At Biocept, we are dedicated to one thing: improving outcomes for cancer patients. That’s why we focus on developing innovative diagnostic solutions that give patients and doctors the information they need—all from a simple blood test, known as a liquid biopsy.
Our team of scientific experts has spent years working to change the way physicians look at blood in cancer patients. We have developed a unique, patented methodology to isolate rare cells—such as circulating tumor cells, (CTCs) as well as cell-free circulating tumor DNA (ctDNA) from the blood, allowing us to provide both analytically and clinically validated and exploratory biomarker analysis, all without a tissue sample.
Biocept’s services are available to medical and surgical oncologists, pathologists, hospitals, cancer centers, universities, and pharmaceutical and clinical researchers. Our liquid biopsies have been used by doctors in thousands of patient cases. We partner with industry leaders and major cancer centers, continually advancing the field of cancer diagnostics.
Doctors are already using Biocept to establish biomarker status for thousands of patients.